Clinical Trial of Encapsulated Islet Cells


By: dhtest

On August 16th, CytoTherapeutics Incorporated announced the commencement of its FDA-approved trial involving polymer-encapsulated islet cells. The trial is designed to establish that their semi-permeable membrane can allow enough nutrients through to keep the encapsulated cells alive while protecting them from destruction without the use of immunosuppressive drugs. The implant will be tested in people with type I and type 2 diabetes, as well as in a nondiabetic control group. The trial will be conducted at Washington University School of Medicine in St. Louis, and results of the 4 month viability study are expected by the end of 1993.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.